Cayman Islands, December 10, 2024 –
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the
“Company”), a clinical-stage biotech developing RNA interference
(RNAi) therapies for KRAS-driven cancers, today announced the
appointment of Prof. Amnon Peled as an independent director to its
Board of Directors. Prof. Peled, a globally recognized authority in
stem cell biology, immunology, and cancer therapeutics who has been
involved in numerous successful publicly traded bio-pharma
companies, will also serve on the Company’s audit, compensation,
and nominating and corporate governance committees. The Board
unanimously approved his appointment, citing his decades of
experience in advancing novel cancer therapies from discovery to
FDA approval.
Ilan Hadar, Chairman and CEO of Silexion,
commented: “We are thrilled to welcome Prof. Peled to our Board of
Directors. His unparalleled expertise in cancer biology, stem cell
mobilization, and therapeutic development will be invaluable as
Silexion continues to advance its pipeline of RNAi-based therapies
for difficult-to-treat cancers. Prof. Peled’s track record in
translating innovative science into impactful clinical outcomes
aligns perfectly with our mission to address unmet needs in
oncology.”
“I am excited to join Silexion at such a pivotal
time in its journey,” said Prof. Amnon Peled. “The Company’s RNAi
platform holds tremendous promise for addressing some of the most
challenging oncology indications. I look forward to contributing my
expertise to help advance Silexion’s innovative pipeline and drive
meaningful impact for patients.”
Prof. Peled’s appointment reinforces Silexion’s
commitment to scientific and strategic excellence as it advances
its RNAi platform and next-generation therapies targeting KRAS
mutations. His extensive experience in clinical development and
regulatory pathways will contribute to Silexion’s mission of
delivering innovative solutions for patients facing the most
challenging cancers. Prof. Peled’s appointment also fills its
current board vacancy, ensuring Silexion remains in compliance with
Nasdaq’s listing requirements, including having a fully constituted
audit committee.
About Prof. Amnon Peled
Prof. Peled serves as the Director of the Gene
Therapy Institute at Hadassah Medical Center in Jerusalem, where
his research focuses on cytokine roles in hematopoietic stem cell
biology, inflammation, and cancer. Over his 28-year career, he has
led groundbreaking research into the chemokine receptor CXCR4, a
key player in stem cell mobilization and cancer. Prof. Peled has
authored over 120 scientific publications and holds more than 200
patents and patent applications related to therapeutic applications
in stem cell biology, immunology, and cancer.
Prof. Peled’s contributions to biotechnology
include close collaborations with leading Israeli biotech companies
such as Biokine Therapeutics, BiolineRX (NASDAQ: BLRX), Gamida
Cell, KAHR Medical, and AlonBio. He is the founder of Biokine
Therapeutics, AlonBio, and SakuraBio. His leadership in the
development of the CXCR4 antagonist BKT140/BL8040 and Gamida Cell’s
NK and cord blood stem cell expansion technologies has resulted in
multiple FDA approvals. Prof. Peled earned his Ph.D. from the
Weizmann Institute of Science and conducted postdoctoral research
at Harvard Medical School and Millennium Pharmaceuticals, Inc.
About Silexion Therapeutics
Silexion Therapeutics (NASDAQ: SLXN) is a
pioneering clinical-stage, oncology-focused biotechnology company
developing innovative RNA interference (RNAi) therapies to treat
solid tumors driven by KRAS mutations, the most common oncogenic
driver in human cancers. The company's first-generation product,
LODER™, has shown promising results in a Phase 2 trial for
non-resectable pancreatic cancer. Silexion is also advancing its
next-generation siRNA candidate, SIL-204, designed to target a
broader range of KRAS mutations and showing significant potential
in preclinical studies. The company remains committed to pushing
the boundaries of therapeutic innovation in oncology, with a focus
on improving outcomes for patients with difficult-to-treat cancers.
For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws. All statements other
than statements of historical fact contained in this communication,
including statements regarding Silexion’s directors, compliance
with Nasdaq listing requirements, share price, business strategy,
research and development plans, anticipated milestones, expected
clinical and preclinical advancements, and management’s objectives
for future operations, are forward-looking statements. These
forward-looking statements are generally identified by terminology
such as “may,” “should,” “could,” “might,” “plan,” “possible,”
“project,” “strive,” “budget,” “forecast,” “expect,” “intend,”
“will,” “estimate,” “anticipate,” “believe,” “predict,”
“potential,” or “continue,” or the negatives of these terms or
variations of them or similar terminology. Forward-looking
statements include, without limitation, Silexion’s expectations
regarding the progression of its clinical and preclinical programs,
pipeline of RNAi-based therapies, contributions of members of its
Board of Directors, financing prospects, future market conditions,
expected regulatory filings, and other potential developments
related to its research pipeline and business strategy.
Forward-looking statements involve a number of risks,
uncertainties, and assumptions, and actual results or events may
differ materially from those projected or implied in such
statements. Important factors that could cause such differences
include, but are not limited to: (i) Silexion’s ability to realize
the anticipated benefits of being a public company, which may be
impacted by competition, operational challenges, the retention of
key personnel, and the costs associated with public listing; (ii)
risks related to Silexion’s ability to advance its lead programs,
including LODER™ and SIL-204, through clinical development
successfully and in a timely manner; (iii) the potential impact of
the Company’s recent reverse share split on the Company’s share
price and its ability to maintain compliance with Nasdaq listing
requirements; (iv) the potential impact of the recent reverse share
split on Silexion’s ability to successfully raise capital in the
near future; (v) changes in regulatory requirements or the
potential for regulatory delays; (vi) Silexion’s ability to
maintain and expand its intellectual property portfolio; (vii) the
availability and terms of additional capital needed to fund ongoing
research and development activities and operational expenses;
(viii) the evolving market for RNA interference (RNAi) therapies
and the competitive landscape in oncology; (ix) the possibility
that Silexion may not achieve anticipated milestones within
expected timelines, including initiation of Phase 2/3 clinical
trials for SIL-204; (x) risks associated with reliance on
third-party manufacturers and collaborators for development and
commercialization efforts; and (xi) other risks and uncertainties
as detailed in the documents filed or to be filed with the SEC by
Silexion, including the definitive proxy statement on Schedule 14A
filed on October 22, 2024, the current report on Form 8-K filed on
August 21, 2024, and the Form S-1 registration statement filed on
October 31, 2024. Silexion cautions you against placing undue
reliance on forward-looking statements, which reflect current
beliefs and are based on information available as of the date a
forward-looking statement is made. Forward-looking statements set
forth herein speak only as of the date they are made. Silexion
undertakes no obligation to revise forward-looking statements to
reflect future events, changes in circumstances, or changes in
beliefs, except as otherwise required by law.
Contacts
Silexion Therapeutics CorpMs. Mirit Horenshtein Hadar,
CFOmirit@silexion.com
ARX | Capital Markets AdvisorsNorth American Equities
Desksilexion@arxadvisory.com
Silexion Therapeutics (NASDAQ:SLXN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Silexion Therapeutics (NASDAQ:SLXN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
